Ublituximab shows promise for Long-Term MS control in large extension trial
NCT ID NCT04130997
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study is a long-term follow-up for people with relapsing multiple sclerosis who previously completed a ublituximab trial. It aims to see if the drug remains safe and effective over time. About 1100 participants will receive ublituximab infusions, and researchers will track relapse rates and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ublituximab (a monoclonal antibody targeting CD20)
- What this could lead to
- If successful, this study could confirm ublituximab as a safe and effective long-term treatment to reduce relapses in people with relapsing multiple sclerosis.
- What could go wrong
- This is an extension study, so participants already know they tolerate ublituximab. However, long-term risks or reduced effectiveness over time are still possible. The study is not designed to prove a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
TG Investigational Trial Site
Zagreb, 10000, Croatia
-
TG Therapeutics Investigational Trial Site
Pasadena, California, 91105, United States
-
TG Therapeutics Investigational Trial Site
Denver, Colorado, 80045, United States
-
TG Therapeutics Investigational Trial Site
Miami, Florida, 33136, United States
-
TG Therapeutics Investigational Trial Site
Tampa, Florida, 33612, United States
-
TG Therapeutics Investigational Trial Site
Northbrook, Illinois, 60062, United States
-
TG Therapeutics Investigational Trial Site
Kansas City, Kansas, 66160, United States
-
TG Therapeutics Investigational Trial Site
Detroit, Michigan, 48201, United States
-
TG Therapeutics Investigational Trial Site
Las Vegas, Nevada, 89106, United States
-
TG Therapeutics Investigational Trial Site
Teaneck, New Jersey, 07666, United States
-
TG Therapeutics Investigational Trial Site
Albuquerque, New Mexico, 87131, United States
-
TG Therapeutics Investigational Trial Site
Amherst, New York, 14266, United States
-
TG Therapeutics Investigational Trial Site
Columbus, Ohio, 43214, United States
-
TG Therapeutics Investigational Trial Site
Westerville, Ohio, 43081, United States
-
TG Therapeutics Investigational Trial Site
Knoxville, Tennessee, 37922, United States
-
TG Therapeutics Investigational Trial Site
Dallas, Texas, 75246, United States
-
TG Therapeutics Investigational Trial Site
Frisco, Texas, 75034, United States
-
TG Therapeutics Investigational Trial Site
Round Rock, Texas, 78681, United States
-
TG Therapeutics Investigational Trial Site
San Antonio, Texas, 78258, United States
-
TG Therapeutics Investigational Trial Site
Seattle, Washington, 98109, United States
-
TG Therapeutics Investigational Trial Site
Grodno, 230017, Belarus
-
TG Therapeutics Investigational Trial Site
Grodno, 320017, Belarus
-
TG Therapeutics Investigational Trial Site
Minsk, 220114, Belarus
-
TG Therapeutics Investigational Trial Site
Minsk, 220116, Belarus
-
TG Therapeutics Investigational Trial Site
Minsk, 220226, Belarus
-
TG Therapeutics Investigational Trial Site
Osijek, 31000, Croatia
-
TG Therapeutics Investigational Trial Site
Varaždin, 42000, Croatia
-
TG Therapeutics Investigational Trial Site
Tbilisi, 00112, Georgia
-
TG Therapeutics Investigational Trial Site
Tbilisi, 00114, Georgia
-
TG Therapeutics Investigational Trial Site
Tbilisi, 00159, Georgia
-
TG Therapeutics Investigational Trial Site
Tbilisi, 00160, Georgia
-
TG Therapeutics Investigational Trial Site
Tbilisi, 00172, Georgia
-
TG Therapeutics Investigational Trial Site
Tbilisi, 00179, Georgia
-
TG Therapeutics Investigational Trial Site
Katowice, 40-555, Poland
-
TG Therapeutics Investigational Trial Site
Katowice, 40-568, Poland
-
TG Therapeutics Investigational Trial Site
Katowice, 40-684, Poland
-
TG Therapeutics Investigational Trial Site
Krakow, 31-505, Poland
-
TG Therapeutics Investigational Trial Site
Lodz, 41-800, Poland
-
TG Therapeutics Investigational Trial Site
Olsztyn, 10-561, Poland
-
TG Therapeutics Investigational Trial Site
Poznan, 61-583, Poland
-
TG Therapeutics Investigational Trial Site
Warsaw, 04-141, Poland
-
TG Therapeutics Investigational Trial Site
Zabrze, 04-749, Poland
-
TG Therapeutics Investigational Trial Site
Arkhangelsk, 163045, Russia
-
TG Therapeutics Investigational Trial Site
Barnaul, 656045, Russia
-
TG Therapeutics Investigational Trial Site
Bryansk, 241033, Russia
-
TG Therapeutics Investigational Trial Site
Chelyabinsk, 454021, Russia
-
TG Therapeutics Investigational Trial Site
Kemerovo, 650066, Russia
-
TG Therapeutics Investigational Trial Site
Krasnoyarsk, 660037, Russia
-
TG Therapeutics Investigational Trial Site
Kursk, 305007, Russia
-
TG Therapeutics Investigational Trial Site
Moscow, 125367, Russia
-
TG Therapeutics Investigational Trial Site
Moscow, 127015, Russia
-
TG Therapeutics Investigational Trial Site
Nizhny Novgorod, 603155, Russia
-
TG Therapeutics Investigational Trial Site
Novosibirsk, 630007, Russia
-
TG Therapeutics Investigational Trial Site
Novosibirsk, 630087, Russia
-
TG Therapeutics Investigational Trial Site
Pyatigorsk, 357538, Russia
-
TG Therapeutics Investigational Trial Site
Saint Petersburg, 197002, Russia
-
TG Therapeutics Investigational Trial Site
Saint Petersburg, 197110, Russia
-
TG Therapeutics Investigational Trial Site
Saint Petersburg, 197376, Russia
-
TG Therapeutics Investigational Trial Site
Saransk, 430032, Russia
-
TG Therapeutics Investigational Trial Site
Smolensk, 214018, Russia
-
TG Therapeutics Investigational Trial Site
Tomsk, 634050, Russia
-
TG Therapeutics Investigational Trial Site
Tyumen, 625000, Russia
-
TG Therapeutics Investigational Trial Site
Ufa, 450005, Russia
-
TG Therapeutics Investigational Trial Site
Yekaterinburg, 620102, Russia
-
TG Therapeutics Investigational Trial Site
Belgrade, 11000, Serbia
-
TG Therapeutics Investigational Trial Site
Kragujevac, 34000, Serbia
-
TG Therapeutics Investigational Trial Site
Cherkasy, 18009, Ukraine
-
TG Therapeutics Investigational Trial Site
Chernihiv, 14001, Ukraine
-
TG Therapeutics Investigational Trial Site
Chernihiv, 14029, Ukraine
-
TG Therapeutics Investigational Trial Site
Chernivtsi, 58002, Ukraine
-
TG Therapeutics Investigational Trial Site
Ivano-Frankivsk, 76008, Ukraine
-
TG Therapeutics Investigational Trial Site
Kharkiv, 61058, Ukraine
-
TG Therapeutics Investigational Trial Site
Kharkiv, 61103, Ukraine
-
TG Therapeutics Investigational Trial Site
Kharkiv, 61176, Ukraine
-
TG Therapeutics Investigational Trial Site
Kyiv, 03037, Ukraine
-
TG Therapeutics Investigational Trial Site
Kyiv, 03115, Ukraine
-
TG Therapeutics Investigational Trial Site
Lviv, 79000, Ukraine
-
TG Therapeutics Investigational Trial Site
Lviv, 79010, Ukraine
-
TG Therapeutics Investigational Trial Site
Odesa, 65009, Ukraine
-
TG Therapeutics Investigational Trial Site
Poltava, 36011, Ukraine
-
TG Therapeutics Investigational Trial Site
Ternopil, 46027, Ukraine
-
TG Therapeutics Investigational Trial Site
Uzhhorod, 88018, Ukraine
-
TG Therapeutics Investigational Trial Site
Vinnytsia, 21005, Ukraine
-
TG Therapeutics Investigational Trial Site
Zaporizhia, 69065, Ukraine
-
TG Therapeutics Investigational Trial Site
Zaporizhia, 96900, Ukraine
-
TG Therapeutics Investigational Trial Site
Zhytomyr, 10002, Ukraine
More trials for these conditions
Other studies related to the condition(s) this trial covers.